EYEN Quote, Financials, Valuation and Earnings

Aptevo Therapeutics has a net margin of -485406.34% compared to Eyenovia's net margin of --. Eyenovia's return on equity of -676.86% beat Aptevo Therapeutics's return on equity of --.

Eyenovia has a consensus price target of --, signalling upside risk potential of 3988.79%. On the other hand Aptevo Therapeutics has an analysts' consensus of $21.00 which suggests that it could grow by 333.88%. Given that Eyenovia has higher upside potential than Aptevo Therapeutics, analysts believe Eyenovia is more attractive than Aptevo Therapeutics.

Eyenovia has a beta of 1.434, which suggesting that the stock is 43.383% more volatile than S&P 500. In comparison Aptevo Therapeutics has a beta of 5.014, suggesting its more volatile than the S&P 500 by 401.43%.

Eyenovia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aptevo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eyenovia pays -- of its earnings as a dividend. Aptevo Therapeutics pays out -- of its earnings as a dividend.

Eyenovia quarterly revenues are $1.6K, which are larger than Aptevo Therapeutics quarterly revenues of --. Eyenovia's net income of -$7.9M is lower than Aptevo Therapeutics's net income of -$5.1M. Notably, Eyenovia's price-to-earnings ratio is -- while Aptevo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eyenovia is 146.38x versus 0.03x for Aptevo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -485406.34% compared to Eyenovia's net margin of 11.99%. Eyenovia's return on equity of -676.86% beat Johnson & Johnson's return on equity of 20.88%.

Eyenovia has a consensus price target of --, signalling upside risk potential of 3988.79%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 19.49%. Given that Eyenovia has higher upside potential than Johnson & Johnson, analysts believe Eyenovia is more attractive than Johnson & Johnson.

Eyenovia has a beta of 1.434, which suggesting that the stock is 43.383% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

Eyenovia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.33% to investors and pays a quarterly dividend of $1.24 per share. Eyenovia pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eyenovia quarterly revenues are $1.6K, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Eyenovia's net income of -$7.9M is lower than Johnson & Johnson's net income of $2.7B. Notably, Eyenovia's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 24.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eyenovia is 146.38x versus 4.04x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -485406.34% compared to Eyenovia's net margin of 18.95%. Eyenovia's return on equity of -676.86% beat Merck &'s return on equity of 29.26%.

Eyenovia has a consensus price target of --, signalling upside risk potential of 3988.79%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.44%. Given that Eyenovia has higher upside potential than Merck &, analysts believe Eyenovia is more attractive than Merck &.

Eyenovia has a beta of 1.434, which suggesting that the stock is 43.383% more volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Eyenovia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. Eyenovia pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Eyenovia quarterly revenues are $1.6K, which are smaller than Merck & quarterly revenues of $16.7B. Eyenovia's net income of -$7.9M is lower than Merck &'s net income of $3.2B. Notably, Eyenovia's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eyenovia is 146.38x versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

TFF Pharmaceuticals has a net margin of -485406.34% compared to Eyenovia's net margin of -3342.79%. Eyenovia's return on equity of -676.86% beat TFF Pharmaceuticals's return on equity of -246.45%.

Eyenovia has a consensus price target of --, signalling upside risk potential of 3988.79%. On the other hand TFF Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 46053.85%. Given that TFF Pharmaceuticals has higher upside potential than Eyenovia, analysts believe TFF Pharmaceuticals is more attractive than Eyenovia.

Eyenovia has a beta of 1.434, which suggesting that the stock is 43.383% more volatile than S&P 500. In comparison TFF Pharmaceuticals has a beta of 1.067, suggesting its more volatile than the S&P 500 by 6.683%.

Eyenovia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TFF Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eyenovia pays -- of its earnings as a dividend. TFF Pharmaceuticals pays out -- of its earnings as a dividend.

Eyenovia quarterly revenues are $1.6K, which are smaller than TFF Pharmaceuticals quarterly revenues of $106.1K. Eyenovia's net income of -$7.9M is lower than TFF Pharmaceuticals's net income of -$3.5M. Notably, Eyenovia's price-to-earnings ratio is -- while TFF Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eyenovia is 146.38x versus 0.54x for TFF Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.